For biomedical researchers who need to identify a biological target for a
new therapy, the Centre for Therapeutic Target Validation (CTTV) is a
public-private initiative to generate evidence on the validity of
therapeutic targets based on genome-scale experiments and analysis. The
CTTV is working to create an R&D framework that applies to a wide
range of human diseases, and is committed to sharing its data openly
with the scientific community.
A pioneering public-private research initiative between GSK, the European
Bioinformatics Institute and the Wellcome Trust Sanger Institute is to
harness the power of ‘big data’ and genome sequencing to improve the
success rate for discovering new medicines. The new Centre for
Therapeutic Target Validation will share its data openly in the
interests of accelerating drug discovery.